International Trends in Concurrent Hysterectomy at Risk-Reducing Surgery in BRCA1/2 pathogenic variant carriers: A mixed-methods study

International trends in concurrent hysterectomy practice at RRSO in *BRCA1/2* carriers

A mixed-methods study analyzes international trends in concurrent hysterectomy practice at risk-reducing salpingo-oophorectomy (RRSO) in BRCA1/2 carriers. The question of concurrent hysterectomy is debated due to the risk of endometrial cancer related to tamoxifen in BRCA1 carriers, as well as the reduction of primary peritoneal carcinoma risk. Practices vary significantly by country and center, highlighting the need for harmonized international recommendations.

Synthesis written by Geno'X. For the full original abstract, please refer to the source publication.

International variability in concurrent hysterectomy practice at RRSO reflects a guideline gap. For French oncogeneticists, this question is regularly raised in consultation, particularly in BRCA1 carriers on tamoxifen. Harmonized recommendations would be welcome.